Akt- and Erk-mediated regulation of proliferation and differentiation during PDGFRβ-induced MSC self-renewal

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 11, 2012, Pages 2789-2801

  Gharibi, Borzo ^a   Ghuman, Mandeep S ^a   Hughes, Francis J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Akt; Cell cycle; Differentiation; Erk; Mesenchymal stem cell; PDGFR ; Self renewal

Indexed keywords

CCND1 PROTEIN, HUMAN; CCND3 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 6; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET-DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE 6; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84868152813     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01602.x     Document Type: Article

References (53)

1. Noël D, Gazit D, Bouquet C, et al. Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells. 2004; 22: 74-85. doi: 10.1634/stemcells.22-1-74.
2. Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009; 433: 1-7. doi: 10.1016/j.gene.2008.12.008.
3. Yu J, Carroll TJ, McMahon AP. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development. 2002; 129: 5301-12.
4. Gharibi B, Abraham AA, Ham J, et al. Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. J Bone Miner Res. 2011; 26: 2112-24. doi: 10.1002/jbmr.424.
5. Tamama K, Fan VH, Griffith LG, et al. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells. 2006; 24: 686-95. doi: 10.1634/stemcells.2005-0176.
6. Tsutsumi S, Shimazu A, Miyazaki K, et al. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Bioch Bioph Res Co. 2001; 288: 413-9. doi: 10.1006/bbrc.2001.5777.
7. Solchaga LA, Penick K, Porter JD, et al. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol. 2005; 203: 398-409. doi: 10.1002/jcp.20238.
8. Bianchi G, Banfi A, Mastrogiacomo M, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res. 2003; 287: 98-105. S0014482703001381 [pii].
9. Kang YJ, Jeon ES, Song HY, et al. Role of c-Jun N-terminal kinase in the PDGF-induced proliferation and migration of human adipose tissue-derived mesenchymal stem cells. J Cell Biochem. 2005; 95: 1135-45. doi: 10.1002/jcb.20499.
10. Stolzing A, Jones E, McGonagle D, et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008; 129: 163-73. doi: 10.1016/j.mad.2007.12.002.
11. Bonyadi M, Waldman SD, Liu D, et al. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci U S A. 2003; 100: 5840-5. doi: 10.1073/pnas.1036475100.
12. Mishra PJ, Mishra PJ, Glod JW, et al. Mesenchymal stem cells: flip side of the coin. Cancer Res. 2009; 69: 1255-8. doi: 10.1158/0008-5472.CAN-08-3562.
13. Satija NK, Singh VK, Verma YK, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med. 2009; 13: 4385-402. doi: 10.1111/j.1582-4934.2009.00857.x.
14. Tokunaga A, Oya T, Ishii Y, et al. PDGF receptor β is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res. 2008; 23: 1519-28. doi: 10.1359/jbmr.080409.
15. Ding W, Knox TR, Tschumper RC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010; 116: 2984-93. doi: 10.1182/blood-2010-02-269894.
16. Veevers-Lowe J, Ball SG, Shuttleworth A, et al. Mesenchymal stem cell migration is regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β and potentiation of growth factor signals. J Cell Sci. 2011; 124: 1288-300. doi: 10.1242/jcs.076935.
17. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22: 1276-312. doi: 10.1101/gad.1653708.
18. Wu E, Palmer N, Tian Z, et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS ONE. 2008; 3: e3794. doi: 10.1371/journal.pone.0003794.
19. Elorza A, Hyde B, Mikkola HK, et al. UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis. J Biol Chem. 2008; 283: 30461-70. doi: 10.1074/jbc.M805400200.
20. Zhang HH, Huang J, Düvel K, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS ONE. 2009; 4: e6189. doi: 10.1371/journal.pone.0006189.
21. Wang T, Wang Y, Yamashita H. Evodiamine inhibits adipogenesis via the EGFR-PKCα-ERK signaling pathway. FEBS Lett. 2009; 583: 3655-9. doi: 10.1016/j.febslet.2009.10.046.
22. Wang X, Harimoto K, Liu J, et al. Spata4 promotes osteoblast differentiation through Erk-activated Runx2 pathway. J Bone Miner Res. 2011; 26: 1964-73. doi: 10.1002/jbmr.394.
23. Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009; 122: 716-26. doi: 10.1242/jcs.042770.
24. Dasari VR, Kaur K, Velpula KK, et al. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS ONE. 2010; 5: e10350. doi: 10.1371/journal.pone.0010350.
25. de Launay D, van de Sande MG, de Hair MJ, et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis. 2012; 71: 415-23. doi: 10.1136/ard.2010.143529.
26. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal. 2011; 23: 1515-27. doi: 10.1016/j.cellsig.2011.05.004.
27. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9: 550-62. doi: 10.1038/nrc2664.
28. Gharibi B, Abraham AA, Ham J, et al. Contrasting effects of A1 and A2b adenosine receptors on adipogenesis. Int J Obes. 2012; 36: 397-406. doi: 10.1038/ijo.2011.129.
29. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007; 117: 730-8. doi: 10.1172/JCI28984.
30. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res. 2008; 314: 1937-44. doi: 10.1016/j.yexcr.2008.03.006.
31. Zheng H, Ying H, Wiedemeyer R, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010; 17: 497-509. doi: 10.1016/j.ccr.2010.03.020.
32. Liu HK, Wang Y, Belz T, et al. The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev. 2010; 24: 683-95. doi: 10.1101/gad.560310.
33. Liu L, Rando TA. Manifestations and mechanisms of stem cell aging. J Cell Biol. 2011; 193: 257-66. doi: 10.1083/jcb.201010131.
34. Suzuki S, Dobashi Y, Hatakeyama Y, et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 2010; 10: 659. doi: 10.1186/1471-2407-10-659.
35. Ustach CV, Huang W, Conley-LaComb MK, et al. A novel signaling axis of atriptase/PDGF-D/β-PDGFR in human prostate cancer. Cancer Res. 2010; 70: 9631-40. doi: 10.1158/0008-5472.CAN-10-0511.
36. Jones AV, Cross NC. Oncogenic protein tyrosine kinases: oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci. 2004; 61: 2912-23. doi: 10.1007/s00018-004-4272-z.
37. Zaragosi LE, Ailhaud G, Dani C. Autocrine fibroblast rowth Factor 2 signaling is critical for self-Renewal of human multipotent adipose-derived stem cells. Stem Cells. 2006; 24: 2412-9. doi: 10.1634/stemcells.2006-0006.
38. Makino T, Jinnin M, Muchemwa FC, et al. Basic fibroblast growth factor stimulates the proliferation of human dermal fibroblasts via the ERK1/2 and JNK pathways. Br J Dermatol. 2010; 162: 717-23. doi: 10.1111/j.1365-2133.2009.09581.x.
39. Liu S, Li Y, Lin T, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract. 2011; 91: 177-82. doi: 10.1016/j.diabres.2010.11.009.
40. Tarcic G, Avraham R, Pines G, et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J. 2012; 26: 1582-92. doi: 10.1096/fj.11-194654.
41. Choi SC, Kim SJ, Choi JH, et al. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem cells dev. 2008; 17: 725-36. doi: 10.1089/scd.2007.0230.
42. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal rowth factor receptor-independent manner. Cancer Res. 2005; 65: 6275-81. doi: 10.1158/0008-5472.CAN-05-0216.
43. Dumesic PA, Scholl FA, Barragan DI, et al. Erk1/2 MAP kinases are required for epidermal G2/M progression. J Cell Biol. 2009; 185: 409-22. doi: 10.1083/jcb.200804038.
44. Chen H, Gu X, Liu Y, et al. PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature. 2011; 478: 349-55. doi: 10.1038/nature10502.
45. Perez J, Torres RA, Rocic P, et al. PYK2 signaling is required for PDGF-dependent vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2011; 301: C242-51. doi: 10.1152/ajpcell.00315.2010.
46. Cho D, Mier JW, Atkins MB. PI3K/Akt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ, editors. Renal cell carcinoma. New York: Humana Press; 2009. pp. 267-85.
47. Fu M, Wang C, Li Z, et al. Minireview: cyclin D1: normal and abnormal functions. Endocrinology. 2004; 145: 5439-47. doi: 10.1210/en.2004-0959.
48. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27: 2278-87. doi: 10.1200/JCO.2008.20.0766.
49. Sundberg C, Branting M, Gerdin B, et al. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol. 1997; 151: 479-92.
50. Wu L, Cai X, Dong H, et al. Serum regulates adipogenesis of mesenchymal stem cells via MEK/ERK-dependent PPARγ expression and phosphorylation. J Cell Mol Med. 2010; 14: 922-32. doi: 10.1111/j.1582-4934.2009.00709.x.
51. Wang M, Wang JJ, Li J, et al. Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol Endocrinol Metab. 2009; 297: E1378-87. doi: 10.1152/ajpendo.00252.2009.
52. Kratchmarova I, Blagoev B, Haack-Sorensen M, et al. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science. 2005; 308: 1472-7. doi: 10.1126/science.1107627.
53. Kumar A, Salimath BP, Stark GB, et al. Platelet-derived growth factor receptor signaling is not involved in osteogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A. 2009; 16: 983-93. doi: 10.1089/ten.TEA.2009.0230.